AMAG Reports 2017 Financial Results and Company Update

Go back to AMAG Reports 2017 Financial Results and Company Update

AMAG Pharmaceuticals (AMAG) PT Raised to $25 at Cowen as Execution Improves

February 27, 2018 11:59 AM EST

Cowen raised its price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $25.00 (from $20.00) while maintaining a Market Perform rating.

Analyst Ken Cacciatore commented, "AMAG has had a very nice start to '18, with the Makena autoinjector approval a solid step in the recovery. While... More

AMAG Pharma (AMAG) Posts Q4 EPS of $0.10 on Tax Reform Gain

February 27, 2018 7:06 AM EST

AMAG Pharma (NASDAQ: AMAG) reported Q4 EPS of $0.10, which does not compare to the analyst estimate of ($0.43). Revenue for the quarter came in at $159.7 million versus the consensus estimate of $160.14 million. Net income in the fourth quarter of 2017 was driven primarily by a... More